Wegovy demonstrated significant and sustained weight loss in two-year study in adults with obesity – Novo Nordisk
Results from the STEP 5 phase IIIb trial, presented by Novo Nordisk at the Obesity Week 2021 interactive congress, showed that adults treated with Wegovy (semaglutide 2.4 mg… read more.